Catalog # 10-2491

CUDC-101

CAS# 1012054-59-9

7-((4-((3-Ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide

Lot # X105304



A novel hybrid dual-acting HDAC and receptor tyrosine kinase inhibitor. It is a potent HDAC inhibitor which also inhibits EGFR and HER2, IC_{50} = 4.4, 2.4 and 15.7 nM respectively.[1] It not only blocks EGFR and HER2 but also attenuates multiple compensatory pathways such as AKT, HER3 and MET which enable tumor cells to escape the effects of conventional EGFR/HER2 inhibitors.[1,2]

1) Lai *et al*. (2010), *CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potential anticancer activity*; Cancer Res., **70** 3647
2) Cai *et al*. (2010), *Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer*; J. Med. Chem., **53** 2000

PHYSICAL DATA

Molecular Weight:	434.49
Molecular Formula:	$C_{24}H_{26}N_4O_4$
Purity:	99% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 25 mg/ml)
Physical Description:	White or off-white solid
Storage and Stability:	Store as supplied, desiccated at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.

Focus Biomolecules LLC 400 Davis Drive, Suite 600 Plymouth Meeting PA 19462

www.focusbiomolecules.com